CYH33: Clinical Trials

2 trials of CYH33, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 recruiting. 2 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 22Active not recruiting 1, Recruiting 1
Phase 11Recruiting 1

Follow CYH33: new trials by email Literature Review of CYH33 trials Research Report on CYH33

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)
CYH33, Placebo - PIK3CA-Related Overgrowth Spectrum (PROS), PIK3CA-related Vascular Malformations (PRVM)
Phase 1 / Phase 2RecruitingHaihe Biopharma Co., Ltd.1412023-08-222026-06-29
A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma
CYH33 - Ovarian Cancer, Recurrent Cancer
Phase 2Active not recruitingHaihe Biopharma Co., Ltd.932021-10-112026-01-30

Conditions studied

Ovarian Neoplasms (1)  ·  Recurrence (1)

Sponsors

Haihe Biopharma Co., Ltd. (2)

Countries

China (2)  ·  Japan (2)